What's Happening?
Venture capitalists (VCs) in the medtech sector are increasingly investing in AI-driven health technologies, often without substantial clinical evidence to support their efficacy. According to Dr. Leeza Osipenko, founder and CEO of Consilium Scientific,
the current investment model prioritizes speed and compelling narratives over rigorous proof. This approach is likened to a 'casino model,' where the high-risk nature of investments is accepted, with the expectation that a few successful ventures will offset numerous failures. The U.S. digital health venture funding reached $14.2 billion in 2025, driven by enthusiasm for AI, despite a 2025 JAMA Network Open study revealing that only 56% of FDA-approved AI devices had clinical performance studies at the time of approval.
Why It's Important?
The trend of investing in unproven AI technologies in healthcare has significant implications for the industry and society. While the model can yield high returns for top-performing funds, it also leads to wasted resources on products that may not deliver on their promises. Health systems and payers often invest in pilots that fail to scale, and clinicians face 'solution fatigue' from ineffective tools. Patients are at risk of encountering devices that may be recalled due to lack of validation. This environment creates a high-waste equilibrium, diverting talent and capital from ventures with clearer evidence trajectories. The lack of robust clinical validation can hinder progress toward universal health goals and slow the adoption of genuinely innovative solutions.
What's Next?
To improve the quality of investments and outcomes, there is a call for more rigorous scrutiny of medtech ventures. Experienced investors are encouraged to focus on core clinical claims and realistic evidence ladders, which can enhance portfolio quality without stifling innovation. By prioritizing companies with defensible paths to measurable clinical or economic value, the industry could see more products that genuinely impact healthcare decisions and outcomes. This shift could lead to fewer stalled pilots, faster adoption by health systems, and stronger long-term returns for investors. Ultimately, a more evidence-based approach could benefit patients and health systems by ensuring that only effective and validated technologies reach the market.
